JRVR:NASDAQJames River Group Holdings, Inc. Analysis
Data as of 2026-06-11 - not real-time
$4.18
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
James River Group Holdings trades at $4.18, just above the calculated support of $3.80 and well below its 20‑day SMA of $4.03, indicating short‑term pressure despite a bullish MACD histogram and an RSI near the midpoint (42.8). Volatility is extreme at 90% over the past 30 days, while beta is unusually low (≈0.2), suggesting price swings are driven more by company‑specific factors than market moves. The bearish trend direction and decreasing volume reinforce a cautious near‑term outlook, but the technical picture shows a slight bullish tilt as the MACD line sits above its signal.
Fundamentally, JRVR reports a 12% revenue decline, thin operating margins (‑3.3%) and modest profit margin (4.3%), yet its forward EPS is projected to rise to $1.11, compressing the forward P/E to 3.8×. The stock trades at a PE of 9.9× versus an industry average of 16.5×, a price‑to‑book of 0.36× and a price‑to‑sales of 0.29×, all pointing to deep undervaluation. Free cash flow of $215.6 M dwarfs the $0.04 dividend, yielding a sustainable 0.96% payout. A DCF model implies a fair value near $58.8, translating to a ~28% upside over current levels, while activist investor activity and a recent UBS downgrade to neutral add both catalyst potential and short‑term uncertainty.
Fundamentally, JRVR reports a 12% revenue decline, thin operating margins (‑3.3%) and modest profit margin (4.3%), yet its forward EPS is projected to rise to $1.11, compressing the forward P/E to 3.8×. The stock trades at a PE of 9.9× versus an industry average of 16.5×, a price‑to‑book of 0.36× and a price‑to‑sales of 0.29×, all pointing to deep undervaluation. Free cash flow of $215.6 M dwarfs the $0.04 dividend, yielding a sustainable 0.96% payout. A DCF model implies a fair value near $58.8, translating to a ~28% upside over current levels, while activist investor activity and a recent UBS downgrade to neutral add both catalyst potential and short‑term uncertainty.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish trend
- Decreasing volume and high short‑term volatility
- Potential catalyst from activist stakeholder but limited upside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap (price vs DCF and peers)
- Improving forward earnings and low payout ratio
- Analyst price targets suggesting 75% upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Deep undervaluation with strong free cash flow generation
- Low beta and defensive dividend profile
- Long‑term upside potential from DCF and sector consolidation
Key Metrics & Analysis
Financial Health
Revenue Growth-12.10%
Profit Margin4.34%
P/E Ratio10.0
ROE4.74%
ROA0.61%
Debt/Equity50.63
P/B Ratio0.4
Op. Cash Flow$32.0M
Free Cash Flow$215.6M
Industry P/E16.5
Technical Analysis
TrendBearish
RSI42.8
Support$3.80
Resistance$4.42
MA 20$4.03
MA 50$5.15
MA 200$5.81
MACDBullish
VolumeDecreasing
Fear & Greed Index83.29
Valuation
Fair Value$58.82
Target Price$5.38
Upside/Downside28.59%
GradeUndervalued
TypeValue
Dividend Yield0.96%
Risk Assessment
Beta0.21
Volatility90.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.